MedTrace Logo

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

NCT03093922 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-04-07

No results posted yet for this study

Summary

The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.

Conditions

Interventions

DRUG

Atezolizumab

1200 mg/m\^2

DRUG

Gemcitabine

1000 mg/m\^2

DRUG

Cisplatin

70 mg/m\^2

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • Targos

    collaborator UNKNOWN

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Samuel Funt, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-22
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03093922 on ClinicalTrials.gov